3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors

US12227501B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• DANA-FARBER CANCER INSTITUTE, INC. · US
• The Broad Institute, Inc. · US

Inventors

• Volker Schulze · Hohen Neuendorf, DE
• Anne Mengel · Berlin, DE
• Jens SCHRÖDER · Jena, DE
• Adelaide Clara Faria Alvares De Lemos · Berlin, DE
• Wilhelm Bone · Berlin, DE
• Ulf Bömer · Glienicke, DE
• Detlev Sülzle · Berlin, DE
• Clara Christ · Leverkusen, DE
• Roman Hillig · Berlin, DE
• Christian Lechner · Berlin, DE
• Steven Corsello · Boston, US
• Katarzyna Handing · Framingham, US
• Alisha Caliman · Cambridge, US
• Ulrike Rauh · Leverkusen, DE
• Stefan Kaulfuss · Berlin, DE
• Jeremie Xavier G. MORTIER · Leverkusen, DE

Key dates

• Filing date: Feb 6, 2020
• Grant date: Feb 18, 2025
• Expiry date: May 24, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/10
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula (I) processes for their production and their use as pharmaceuticals. The compounds are inhibitors of Casein kinase 1 alpha and/or delta (CSNK1α and/or β) useful for the treatment of proliferative disorders.